Lung Cancer
Volume 66, Issue 3 , Pages 338-343 , December 2009

Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: A prospective, multicenter trial

  • Hui-Young Lee

      Affiliations

    • Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon 200-722, Republic of Korea
    • ,
  • Myung-Ju Ahn

      Affiliations

    • Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Republic of Korea
    • ,
  • Yeon Hee Park

      Affiliations

    • Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Republic of Korea
    • ,
  • Jin Seok Ahn

      Affiliations

    • Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Republic of Korea
    • ,
  • Bong-Seog Kim

      Affiliations

    • Division of Hematology/Oncology, Department of Internal Medicine, Seoul Veterans Hospital, Seoul 134-791,Republic of Korea
    • ,
  • Hoon Kyo Kim

      Affiliations

    • Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon 442-723, Republic of Korea
    • ,
  • Heung Tae Kim

      Affiliations

    • Research Institute and Hospital, National Cancer Center, Goyang 410-769, Republic of Korea
    • ,
  • Hun Mo Ryoo

      Affiliations

    • Division of Hematology-Oncology, Department of Internal Medicine, Daegu Catholic University College of Medicine, Daegu 705-718, Republic of Korea
    • ,
  • Sung Hwa Bae

      Affiliations

    • Division of Hematology-Oncology, Department of Internal Medicine, Daegu Catholic University College of Medicine, Daegu 705-718, Republic of Korea
    • ,
  • Seung Sei Lee

      Affiliations

    • Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 110-746,Republic of Korea
    • ,
  • Kwon Choi

      Affiliations

    • Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 110-746,Republic of Korea
    • ,
  • Dae-Sik Hong

      Affiliations

    • Department of Internal Medicine, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Bucheon 420-767, Republic of Korea
    • ,
  • Kyung Hee Lee

      Affiliations

    • Department of Internal Medicine, Yeungnam University College of Medicine, Daegu 705-717, Republic of Korea
    • ,
  • Jung Hye Kwon

      Affiliations

    • Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University School of Medicine, Seoul 134-701, Republic of Korea
    • ,
  • In Shil Choi

      Affiliations

    • Department of Internal Medicine, Seoul Municipal Boramae Hospital, Seoul National University School of Medicine, Seoul 156-707, Republic of Korea
    • ,
  • Byung-Su Kim

      Affiliations

    • Department of Internal Medicine, Seoul Municipal Boramae Hospital, Seoul National University School of Medicine, Seoul 156-707, Republic of Korea
    • ,
  • Nam Su Lee

      Affiliations

    • Department of Internal Medicine, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul140-743, Republic of Korea
    • ,
  • Soo Jung Gong

      Affiliations

    • Department of Internal Medicine, Eulji University School of Medicine, Daejon 302-799, Republic of Korea
    • ,
  • Keunchil Park

      Affiliations

    • Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Republic of Korea
    • Corresponding Author InformationCorresponding author at: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, Republic of Korea. Tel.: +82 2 3410 3459; fax: +82 2 3410 1754.

Received 24 December 2008 ,Revised 12 February 2009 ,Accepted 15 February 2009.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2007;57:43–66
  2. Shin HR, Won YJ, Park JG. 2002 Annual report of the Korean central cancer registry. Cancer Res Treat. 2004;36:103–114
  3. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539–4544
  4. Ramalingam S, Belani CP. State-of-the-art chemotherapy for advanced non-small cell lung cancer. Semin Oncol. 2004;31:68–74
  5. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–2103
  6. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol. 2000;18:2354–2362
  7. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–1596
  8. Shepherd FA, Rodrigues Pereira J, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med. 2005;353:123–132
  9. Shih C, Habeck LL, Mendelsohn LG, et al. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul. 1998;38:135–152
  10. Thödtmann R, Depenbrock H, Dumez H, et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol. 1999;17:3009–3016
  11. Nakagawa K, Kudoh S, Matsui K, et al. A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B (12) in Japanese patients with solid tumours. Br J Cancer. 2006;95:677–682
  12. Takimoto CH, Hammond-Thelin LA, Latz JE, et al. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res. 2007;13:2675–2683
  13. Malempati S, Nicholson HS, Reid JM, et al. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: The Children's Oncology Group. J Clin Oncol. 2007;25:1505–1511
  14. Manegold C, Gatzemeier U, von Pawel J, et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol. 2000;11:435–440
  15. Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer. 2001;92:595–600
  16. Goedhals L, van Wiyk AL, Smith BL, et al. Pemetrexed (Alimta LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial. Int J Gyn Cancer. 2006;16:1172–1178
  17. Smit EF, Mattson K, von Pawel J, et al. ALIMTA (pemetrexed disodium) as second-line treatment of non-small cell lung cancer: a phase II study. Ann Oncol. 2003;14:455–460
  18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216
  19. Bears A, Garassino I, Cavina R, et al. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study. Lung Cancer. 2008;60:240–245
  20. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–3551
  21. Ciuleanu TE, Brodowicz T, Belani CP, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a phase III study. Proc Am Soc Cli Oncol. 2008;26:426s;(abstr 8011)
  22. Sigmond J, Backus HH, Wouters D, et al. Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol. 2003;66:431–438
  23. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer. 2006;107:1589–1596
  24. Park J, Park BB, Kim JY, et al. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res. 2004;10:4383–4388
  25. Ahn MJ, Park BB, Ahn JS, et al. Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer. Clin Cancer Res. 2008;14:3860–3866

PII: S0169-5002(09)00106-8

doi: 10.1016/j.lungcan.2009.02.008

Lung Cancer
Volume 66, Issue 3 , Pages 338-343 , December 2009

Article Tools